LakeShore Biopharma Co. L... (LSB)
LakeShore Biopharma Co. Ltd Statistics
Share Statistics
LakeShore Biopharma Co. Ltd has 19.08M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 19.08M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 272 |
| FTD / Avg. Volume | 2% |
Short Selling Information
The latest short interest is 13.56K, so 0.07% of the outstanding shares have been sold short.
| Short Interest | 13.56K |
| Short % of Shares Out | 0.07% |
| Short % of Float | 0.41% |
| Short Ratio (days to cover) | 0.45 |
Valuation Ratios
The PE ratio is -1.29 and the forward PE ratio is -11.24. LakeShore Biopharma Co. Ltd's PEG ratio is 0.
| PE Ratio | -1.29 |
| Forward PE | -11.24 |
| PS Ratio | 0.98 |
| Forward PS | 0.2 |
| PB Ratio | 0.96 |
| P/FCF Ratio | -1.65 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for LakeShore Biopharma Co. Ltd.
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.13, with a Debt / Equity ratio of 0.73.
| Current Ratio | 1.13 |
| Quick Ratio | 0.87 |
| Debt / Equity | 0.73 |
| Total Debt / Capitalization | 42.04 |
| Cash Flow / Debt | -0.7 |
| Interest Coverage | -10.05 |
Financial Efficiency
Return on equity (ROE) is -0.74% and return on capital (ROIC) is -42.05%.
| Return on Equity (ROE) | -0.74% |
| Return on Assets (ROA) | -0.29% |
| Return on Capital (ROIC) | -42.05% |
| Revenue Per Employee | $756,488.46 |
| Profits Per Employee | $-571,853.39 |
| Employee Count | 758 |
| Asset Turnover | 0.38 |
| Inventory Turnover | 0.58 |
Taxes
| Income Tax | -21.73M |
| Effective Tax Rate | 0.05 |
Stock Price Statistics
The stock price has increased by -65.28% in the last 52 weeks. The beta is 0.7, so LakeShore Biopharma Co. Ltd's price volatility has been higher than the market average.
| Beta | 0.7 |
| 52-Week Price Change | -65.28% |
| 50-Day Moving Average | 2.35 |
| 200-Day Moving Average | 3.83 |
| Relative Strength Index (RSI) | 55.34 |
| Average Volume (20 Days) | 13.58K |
Income Statement
In the last 12 months, LakeShore Biopharma Co. Ltd had revenue of 573.42M and earned -433.46M in profits. Earnings per share was -40.54.
| Revenue | 573.42M |
| Gross Profit | 455.73M |
| Operating Income | -445.83M |
| Net Income | -433.46M |
| EBITDA | -368.66M |
| EBIT | -445.83M |
| Earnings Per Share (EPS) | -40.54 |
Balance Sheet
The company has 246.35M in cash and 424.46M in debt, giving a net cash position of -178.11M.
| Cash & Cash Equivalents | 246.35M |
| Total Debt | 424.46M |
| Net Cash | -178.11M |
| Retained Earnings | -2.31B |
| Total Assets | 1.51B |
| Working Capital | 100.94M |
Cash Flow
In the last 12 months, operating cash flow was -295.23M and capital expenditures -44.25M, giving a free cash flow of -339.48M.
| Operating Cash Flow | -295.23M |
| Capital Expenditures | -44.25M |
| Free Cash Flow | -339.48M |
| FCF Per Share | -31.75 |
Margins
Gross margin is 79.48%, with operating and profit margins of -77.75% and -75.59%.
| Gross Margin | 79.48% |
| Operating Margin | -77.75% |
| Pretax Margin | -79.38% |
| Profit Margin | -75.59% |
| EBITDA Margin | -64.29% |
| EBIT Margin | -77.75% |
| FCF Margin | -59.2% |
Dividends & Yields
LSB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -1621.6% |
| FCF Yield | -711.41% |
Analyst Forecast
Currently there are no analyst rating for LSB.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Oct 4, 2024. It was a backward split with a ratio of 1:10.
| Last Split Date | Oct 4, 2024 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -2.41 |
| Piotroski F-Score | 3 |